Medicare has chosen 15 prescription medications for price negotiations this year, building off a first round of negotiations for 10 drugs whose lower prices take effect in 2026. T

The Biden administration says popular weight loss drugs like Ozempic and Wegovy have been added to Medicare’s list of medications that will be negotiated directly between the government and drug manufacturers.

Drugs used to treat cancer, diabetes and other chronic conditions are among 15 picked for negotiations that could result in lower prices for patients, the Department of Health and Human Services confirmed Friday.

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for Medicare price negotiations for 2027, the U.S. government said on Friday, part of a law pharmaceutical companies have pledged to revisit with the Trump administration.

The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide whether to expand coverage for millions of Americans.

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

The Centers for Medicare & Medicaid Services just announced 15 new drugs it wants to lower the cost for including popular, but expensive weight-loss drugs.

The Biden administration has announced the next 15 drugs chosen for Medicare negotiation, marking one of its final acts before the inauguration of President-elect Trump. The Centers for Medicare and Medicaid Services (CMS) had until Feb.

Medicare enrollees, however, still won’t be able to access the drugs for obesity under a federal law that prohibits the program from paying for weight loss treatments. Right now